Form 4: IRADIMED Director Kiani Granted 2,095 RSUs

IRADIMED Corporation's Director, Joe E. Kiani, received a grant of 2,095 restricted stock units, which will vest in three equal annual installments starting September 23, 2026.

Summary

• Joe E. Kiani, a Director of IRADIMED CORP (IRMD), was granted 2,095 Restricted Stock Units (RSUs) on September 23, 2025.
• Each RSU represents a contingent right to receive one share of IRADIMED Corporation's common stock.
• The RSUs were granted under IRADIMED Corporation's 2023 Equity Incentive Plan.
• The restricted stock units will vest in three equal annual installments, with the first vesting date occurring on September 23, 2026.
• Following this transaction, Joe E. Kiani beneficially owns 2,095 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns management interests with shareholders, indicating routine corporate activity without significant positive or negative implications for immediate financial performance.

Positives

• The grant of restricted stock units aligns the director's long-term interests with those of the shareholders, incentivizing performance and value creation.

Negatives

• The vesting of these restricted stock units will result in a minor dilution of existing shareholders' equity when the common stock is issued.

Future Outlook

The restricted stock units are scheduled to vest in three equal annual installments beginning September 23, 2026, which will lead to the future issuance of common stock to the reporting person.

Industry Context

Equity-based compensation, such as RSU grants, is a common practice in the medical device industry and across public companies to incentivize directors and align their interests with long-term shareholder value.

Comparison to Industry Standards

• Granting restricted stock units to directors as part of their compensation package is a standard practice across publicly traded companies, including those in the medical technology sector. This aligns with common corporate governance practices for executive and director remuneration.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting and issuance of common stock, but also increased alignment of director's interests with long-term shareholder value.

Next Steps

• Vesting of 2,095 restricted stock units in three equal annual installments beginning September 23, 2026.
• Issuance of common stock upon vesting of the restricted stock units.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation. It does not contain information that would materially alter the company's financial outlook or strategic direction, thus warranting a 'hold' recommendation based solely on this disclosure.

Keywords

IRADIMED, IRMD, Joe Kiani, Director, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, SEC Form 4